Health
PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2 – Small Caps
Further pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured…
Further pre-clinical testing of PharmAusts (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPLS) drugs continues to demonstrate antiviral activity in cultured cell infection models of SARS-CoV2 the virus causing the global COVID-19 pandemic.
Following positive earlier results in both primate and non-primate cell cultures, Leiden University Medical Centre has carried out more tests and generated data indicating both MPL and MPLS demonstrate antiviral activity in non-human primates.
This paves…
-
General16 hours ago‘We are here for you’: PM to bring help to flood zones
-
General15 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News23 hours agoStudents say new facility would be better in rural areas of Queensland
-
General13 hours agoUK PM talks US tariff response with Albanese and Meloni